For the multicenter study, panitumumab 6. Eligible patients had metastatic adenocarcinoma of the colon or rectum; patients may have received adjuvant chemotherapy, excluding oxaliplatin but no chemotherapy for metastatic disease; and available tumor tissue for biomarker testing. Randomization was stratified by ECOG performance status vs 2 and region. The primary endpoint was progression-free survival PFS. A total of 1, patients were included in arm 1; in arm 2.
The median OS was Douillard and Dr. If you have had lung problems in the past, be sure to tell your doctor. Being in the sun may make skin reactions worse. Tell your doctor if you have new or worsening skin reactions. Inflammation of the eye and injury to the cornea have been reported.
Tell your doctor if you have any vision changes or eye problems. The most common serious side effects were diarrhea and dehydration. Please read the full Prescribing Information and discuss it with your doctor. Talk to your doctor about your RAS status. Back to Top. The information provided in this section is intended expressly for health care professionals in the United States. Click "Yes, I am" to enter if you are a U. Get resources to help in your fight. Yes, I am No, I'm Not.
0コメント